Franziskus Hospital, Berlin Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2007
NCT00434616
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Franziskus Hospital, Berlin Vascular Center | Franziskus-Krankenhaus | Franziskus-Krankenhaus, Berlin Germany

Active Ingredients

Drugs in Phase 3 Trials (1)

allogeneic adipose derived mesenchymal stem cell (1 trial)

Drugs in Phase 2 Trials (1)

allogeneic plx-pad cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arterial Occlusive Diseases (Phase 3)

Diabetic Foot (Phase 3)

Gangrene (Phase 3)

Intermittent Claudication (Phase 2)

Ischemia (Phase 3)

Leg Ulcer (Phase 3)

Peripheral Arterial Disease (Phase 3)

Peripheral Vascular Diseases (Phase 3)

Vascular Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2